Suicide risk in visually impaired

Article

Visual impairment is associated with an increased risk of suicide, according to results of a study published in the July 2008 issue of the Archives of Ophthalmology.

Visual impairment is associated with an increased risk of suicide, according to results of a study published in the July 2008 issue of the Archives of Ophthalmology.

Byron L. Lam, MD of the Bascom Palmer Eye Institute, Miami, US and colleagues performed structural equation modeling on data collected by the National Center for Health Statistics between 1986 and 1996 that had been correlated with information taken from the National Death Index up to 2002 to evaluate the relationship between poor reported visual function and suicide mortality.

During the mean follow-up period of 11 years, 200 suicide deaths were identified. The researchers controlled for various factors, including age, sex and race, and approximated that, indirectly, visual impairment increased the likelihood of suicide mortality due to (self-rated) overall poor health by a hazard ratio of 1.05 and due to non-ocular health impairments by 1.12; the direct impact of poor visual function increased the likelihood of suicide by 1.50. Across the board, the total risk of suicide due to poor visual function increased by 1.64.

The researchers concluded that poor visual function increases the risk of suicide, although not significantly. They suggested that the rate of vision-related suicide could be decreased through better treatment of visual impairment as an holistic health issue.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.